An investigation for investors in Seres Therapeutics Inc (NASDAQ:MCRB) shares over potential securities laws violations by Seres Therapeutics was announced and NASDAQ:MCRB stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 08/15/2016 -- Seres Therapeutics Inc is under investigation over potential securities laws violations. The investigation was announced on behalf of investors of Seres Therapeutics Inc (NASDAQ:MCRB) shares in connection certain financial statements made by Seres Therapeutics.
Investors who purchased shares of Seres Therapeutics Inc (NASDAQ:MCRB), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call 858-779-1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Seres Therapeutics Inc (NASDAQ:MCRB) concerning whether a series of statements by Seres Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On July 29, 2016, Seres Therapeutics Inc disclosed that its Phase 2 clinical study for ECOSPOR™ did not meet its primary endpoint of reducing the relative risk of Clostridium difficle infection recurrence. Shares of Seres Therapeutics Inc (NASDAQ:MCRB) declined on July 29, 2016 to as low as $8.05 per share.
According to the investigation just a couple days prior to this announcement, the Company's President, CEO and Chairman of the Board sold 20,000 shares of Seres at $35 per share, and another Company insider sold 38,064 shares at $35.12 per share.
On August 12, 2016, NASDAQ:MCRB closed at $10.53 per share
Those who purchased shares of Seres Therapeutics Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego